[ TRANSACTION RECORD ]

Sanofi Investment in Inhibrx — 2024

VERIFIED VECTOR ID: 001820 · tx-106
M SOURCE NODE — FUNDER
Sanofi
Healthcare France
$1,700,000,000
EQUITY
30/05/2024
Q DESTINATION NODE — RECIPIENT
Inhibrx
Company United States
Amount (USD)
$1.7B
Flow Type
EQUITY
Transaction Date
30/05/2024
Primary Source
View Filing ↗
Funder Profile [ M ]
Entity Sanofi
AUM 135000
HQ Location France
Sector Healthcare
Recipient Profile [ Q ]
Entity Inhibrx
Entity Type Company
Jurisdiction United States
Intelligence Note

Sanofi finalized the acquisition of Inhibrx for approximately 1.7 billion dollars to gain access to a promising therapy for Alpha-1 Antitrypsin Deficiency. The transaction includes a spin-off of non-core assets into a new public entity. This deal represents a strategic institutional investment in rare disease therapies to diversify Sanofi’s general medicine portfolio.

Σ
Primary Forensic Source https://www.sanofi.com/en/media-room/press-releases/2024/2024-05-30-14-10-00-2890693/
✓ SOURCE LINKED